SCHEMBL3485946

SCHEMBL3485946

CC(C)(C)c1ccc(N(C=O)c2cn3nc(-c4ccc5c(c4)OCO5)ccc3n2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.46
HTT P42858 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
KDM4E B2RXH2 5/20 0.41
MAPT P10636 4/20 0.41
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.41
NPC1 O15118 4/20 0.37
RAB9A P51151 4/20 0.37
FYN P06241 8/20 0.37
KMT2A Q03164 1/20 0.37
POLB P06746 1/20 0.36
WDR5 P61964 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
ADORA3 P0DMS8 1/20 0.35
ADORA2A P29274 1/20 0.35
ADORA1 P30542 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3486338 0.76 MET (0.30)
Formic Acid SCHEMBL3485941 0.76 MAP3K5 (0.48) ALDH1A1HTTNPSR1KDM4EMAPT
SCHEMBL13498819 0.75 MAP3K5 (0.52) ALDH1A1HTTNPSR1KDM4EMAPT
SCHEMBL18501694 0.65 ALDH1A1 (0.56) ALDH1A1HTTNPSR1KDM4EMAPT
SCHEMBL10203019 0.65 ALDH1A1 (0.54) ALDH1A1HTTNPSR1KDM4EMAPT
SCHEMBL3486121 0.64 KDM4E (0.42) ALDH1A1KDM4EHPGDFYNKMT2A
SCHEMBL3487008 0.63 PIK3CD (0.39) ALDH1A1HTTKDM4EMAPTHPGD
SCHEMBL3486636 0.62 KIF11 (0.38) KDM4E
SCHEMBL12909574 0.61 SRC (0.51) ALDH1A1HTTKDM4EMAPTHPGD
SCHEMBL3813568 0.60 TSHR (0.42) ALDH1A1HTTNPSR1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029619-A1 FUSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) 2010-02-04 US disclosed
EP-2058309-A1 FUSED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-05-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029619-A1 FUSED HETEROCYCLIC COMPOUND IRAK1, IL1R1, IRAK2 ALDH1A1 794/4885HTT 3499/4885NPSR1 1839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.